logo
ProjectOngoing

NanoBiCar: A novel immunotherapy for infectious diseases

The status, timeline and source of this project. A free account opens every field.

Source: EU Funding & Tenders Portal

It is estimated that 20% of global mortality is associated with bacterial infections. The current treatment is based on the use of antibiotics, but nonspecific effects, difficulty in reaching intracellular bacteria, and the generation of antimicrobial resistance limit its effectiveness. Tuberculosis (TB) is the leading cause of mortality due to a single infectious agent: Mycobacterium tuberculosis

Status
Under Construction
Sector
Water Supply and Storage, Hospital
Location
Spain
Updated
22 Jul 2026
Source
EU Funding & Tenders Portal

ConstructChat

Ask ConstructChat about NanoBiCar: A novel immunotherapy for infectious diseases

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

3 Q
The project “NanoBiCar: A novel immunotherapy for infectious diseases” is an infrastructure initiative in the Water Supply and Storage sector, located in Spain, Israel, France, Netherlands. Taiyo aggregates data on it from EU Funding & Tenders Portal.

Participants

Not available for this record.

Status

Original status

ongoing

Taiyo status

Under Construction

Taiyo last update

2026-07-22

Contact

Not available for this record.

Description

Description

It is estimated that 20% of global mortality is associated with bacterial infections. The current treatment is based on the use of antibiotics, but nonspecific effects, difficulty in reaching intracellular bacteria, and the generation of antimicrobial resistance limit its effectiveness. Tuberculosis (TB) is the leading cause of mortality due to a single infectious agent: Mycobacterium tuberculosis (Mtb). Multidrug-resistant TB (MDR-TB) is a major threat to global health security. A quarter of the population is latently infected with Mtb, many of them MDR strains, so preventing new cases of this growing reservoir is a priority. Immunotherapy is an alternative option, but its effectiveness is based on the immune response capacity of a compromised host. NanoBiCar's long-term vision is to revolutionize the current treatment of bacterial infections with a groundbreaking and innovative immunotherapeutic approach, overcoming many of the problems associated with treatment, with potential application beyond this field. Using TB as a proof of concept, three immunotherapeutic platforms, using mRNAs encapsulated in lipid nanoparticles, not tested in bacterial diseases will be used to eliminate intra (IC) and extracellular (EC) bacteria. These immunotherapeutic methods are safe, economical, accessible, ready-to-use, and specific, targeting latent/ acute/chronic infections, without generating resistance and suitable for use in high-burden, low-resource settings; effective regardless of the antibiotic resistance of the strain and its niche (IC or EC), the genetic background of the host and the degree of immunocompetence.

Location

Country

Spain

Source

Source

EU Funding & Tenders Portal

URL

More Details

Record type

Project

Sector

Water Supply and Storage, Hospital

Article published date

2025-10-15

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project